The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…
Jowell & Randy member Randy is expanding into cannabis with La Zaza, a brand built…
wo of the most popular autoflowering takes on the Cookies family are Auto Girl Scout…
Jamaica has introduced two new special permits designed to help traditional growers and small farmers…
Italy has extensive opioid use, established illicit drug markets and criminal organizations capable of moving…
A strange prophecy sends an isolated artist on a three-day collision with grief, love, creativity,…